Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Orphan Drugs in Trouble?

Earlier this month, Aegerion Pharmaceuticals (NASDAQ: AEGR  ) missed analyst expectations for Juxtapid, with sales coming in at $27 million, and the company lowered guidance for the year to a range of $180 million to $200 million, from a ranger of $190 million to $210 million.

In the following video, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the situation with Aegerion Pharmaceuticals and the orphan-drug model in general.

For Juxtapid, it's hard to know if competition is an issue, because its closest competitor, Kynamro, is sold by Sanofi (NYSE: SNY  ) which doesn't break out sales since they're not material to the larger company. Kynamro was developed by Isis Pharmaceuticals (NASDAQ: ISIS  ) , which is materially affected by sales, but the biotech isn't able to give investors information on the launch because it's fully under Sanofi's control.

From biotech to Silicon Valley
If you thought the iPod, the iPhone, and the iPad were amazing, just wait until you see this. One hundred of Apple's top engineers are busy building one in a secret lab. And an ABI Research report predicts 485 million of them could be sold over the next decade. But you can invest in it right now, for just a fraction of the price of Apple stock. Click here to get the full story in this eye-opening new report.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2963853, ~/Articles/ArticleHandler.aspx, 9/2/2015 2:28:40 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 5 hours ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 3:59 PM
AEGR $17.21 Down -0.48 -2.71%
Aegerion Pharmaceu… CAPS Rating: **
AAPL $107.72 Down -5.04 -4.47%
Apple CAPS Rating: ****
ISIS $48.75 Down -1.43 -2.85%
Isis Pharmaceutica… CAPS Rating: *****
SNY $48.11 Down -0.81 -1.66%
Sanofi (ADR) CAPS Rating: *****